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OBJECTIVES: In 2011 was introduced the early benefit assessment with the new
pharmaceutical restructuring act (AMNOG) in Germany. Only new launched phar-
maceuticals were assessed since this date. At the beginning of June were the first
calls by FJC of drugs which made available for the market before 2011. The objection
is to show relevant criteria for calling a launched product and to analyze which
issues and consequences are possible in the AMNOG process. METHODS: In the
first step was described the political situation before and after the AMNOG and the
potential criteria for a call of launched drugs prior the law. Afterwards it was shown
the dossier development and assessment, hearing, G-BA decision and price nego-
tiation. There were demonstrated possible issues and differences between assess-
ments of new and launched products in this procedure. RESULTS: There is only a
small time frame for dossier development and assessment. Manufacturers and
concerned institutions have to plan and prepare in early expected time. Pharma-
ceuticals mostly admitted for more than one indication, why there could be a high
number of clinical trials available. The assessment of prior 2011 launched drugs is
very difficult, because there was a retrospective change of frame conditions. The
main criteria for a call are the market volume and revenues, remaining patent
protection and the expected assessments of competitors, triggered by admission of
new drugs in next time. CONCLUSIONS: In the next years can be expected, that
G-BA will be assess more pharmaceuticals from indications that have a great in-
fluence for costs in German health care. The methods and criteria have to be
discussed with all involved parties.
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OBJECTIVES:Health plans and other decision making bodies regularly request that
pharmaceutical and biotechnology companies provide a standardized dossier con-
taining detailed information - not only on the drug’s safety and efficacy, but also on
its overall clinical, economic, and humanistic value relative to alternative thera-
pies. Independent focus groups and multi-country surveys identified several chal-
lenges related to convenient, real-time collaboration to access information and
tools developed by the pharmaceutical and biotechnology industry METHODS: In
the US, the Academy of Managed Care Pharmacy (AMCP) partnered with Dy-
maxium Healthcare Innovations to launch an electronic platform to meet imme-
diate needs of US (Health Care Decision Makers (HCDMs). The platform would
incorporate all the key components of decision making processes, and was de-
signed with leading HCDMs. A survey was also fielded to over 50 US decision mak-
ers and payers from 13 other countries to provide their feedback and input into
their local HTA needs. Local country HTA guidelines and formats (i.e AMCP format
in the US) from over 30 countries was incorporated into the overall design of the
platform. RESULTS: The US HCDM survey results indicated the following chal-
lenges: a) Difficulty navigating through large volumes of information (300 pages)
to use for internal reviews, b) Risks associated with review of information that is
out-dated due to the release of newly published safety and effectiveness informa-
tion, c) Lack of user-friendly, transparent models and tools that can be customized
to reflect a plan’s own population patterns. The international survey revealed sim-
ilar challenges and unmet needs by HCDMs that were similar to their US counter-
parts. This feedback is being incorporated into the development of international
versions of the eDossier system. CONCLUSIONS: Leading experts from regional
countries validated the unique needs of each region in conducting HTA reviews
and the various benefits an electronic platform such as the AMCP eDossier may
provide.
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OBJECTIVES: The patient perspective is considered critical for policy decision mak-
ers. However it is unclear how this perspective is incorporated within different HTA
processes. The research identified and compared how selected European HTA
agencies incorporate the patient view in the decision making process for drugs.
METHODS:We identified websites of six relevant European bodies: England (NICE),
France (HAS), Germany (IQWIG and GBA), Scotland (SMC) and Sweden (TLV). We
searched for: how PAG representatives are selected, how they provide input &
contribute to the decision making process and how they are supported by HTA.
Findings were transferred to Excel spreadsheet and sent to respective agencies for
validation. Five of the six HTA responded. RESULTS: No weighting exists on how
Patient Advocacy Group (PAG) input is measured with respect to other data sub-
missions, important differences were observed in the engagement of PAGs as part
of the HTA assessment. HAS appears to have little or no process for PAG involve-
ment in HTA. NICE, SMC and GBA provide a support unit to facilitate PAG input. The
selection process of PAG for involvement in the process is well defined for G-BA,
TLV, NICE and SMC though TLV uses PAGs not related to the disease area under
review. G-BA & IQWIG involve individual patients, PAGs & consumer groups. Com-
prehensive PAG input to the process is publicly available for NICE and SMC. Only
TLV offers an equal voting right for PAGs. CONCLUSIONS: The patient perspective
is a significant contributor in the HTA decision making process. Although all HTA
agencies rely on patient information, significant differences exist in methods of
selection, input, impact and effort to support PAG input. Although such differences
are likely linked to cultural differences there is a need to improve and standardize
PAG input and integration in HTA decision making.
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OBJECTIVES: Personalized medicine is the use of diagnostic testing, including ge-
netic testing, to refine patient selection for the use of high cost procedures, devices,
and medicines. This study compares the processes for making coverage decisions
on multiple technologies between UK and Australia. METHODS: Comparative
study of assessments published by UK’s National Institute for Health and Clinical
Excellence (NICE) and Australia’s Commonwealth Department of Health.RESULTS:
The coverage of medical procedures, devices, and pharmaceuticals has been as-
sessed separately by different committees using conventional approaches of eco-
nomic evaluation in both UK and Australia. In 2005, NICE introduced a process to
assess multiple technologies (medicines, devices, medical procedures), such as
several drugs for the same condition, or one drug for several conditions. By con-
trast, Australia recently introduced an integrated assessment specifically for mul-
tiple, co-dependent technologies (‘personalized medicine’ products), such as med-
icines and their companion diagnostic tests. Health technologies are co-dependent
if their use needs to be combined to achieve or enhance the intended clinical effect
of either technology (e.g. gefitinib for patients with tested positive for an activating
mutation of the epidermal growth factor receptor gene in tumor). The co-depen-
dent technology assessment process was established in response to concerns that
1) only one technology in the co-dependent is reimbursed (e.g. a medicine is cov-
ered by the drug formulary while the companion test to determine responders is
not covered by Medicare), and 2) the assessment of a co-dependent technology
should consider the benefits and costs of their joint use, as distinct to the benefits
and costs of each technology alone. Analysis is underway to compare the timeli-
ness and recommendationsfor personalized medicine products between UK and
Australia. CONCLUSIONS: Important lessons are to be learned from the existing
experiences as health technologies are increasingly used either sequentially or
simultaneously in the continued development of personalized medicine.
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OBJECTIVES: The AMNOG has been in place for new drugs in Germany since 01/
01/2011. The AMNOG includes early benefit assessment in comparison to one pre-
defined ‘appropriate comparator’ therapy and negotiation of reimbursement price.
The objective of this research was to review and compare the outcomes of all
benefit assessments which had had in place a final decision until June 2012.
METHODS: A review based on all published documents of the AMNOG processes
(benefit dossiers submitted, IQWiG assessment reports and final G-BA decisions).
This investigation focuses on the comprehensive description and comparison of
outcomes of assessment and final decision. RESULTS: Until June 10, 2012, a total of
n14 AMNOG processes were finalized. For further 4 processes no dossier was
submitted. An additional benefit was partially credited 7 (50 %) out of the 14 new
drugs by the IQWiG and 10 (71%) by the G-BA. The IQWiG differentiated 39 sub-
populations for separate assessment and the G-BA considered 31 subpopulations
in the final decisions. The IQWiG credited 26 out of 39 subpopulations (67 %) with
‘no proof of additional benefit’. A total of 3 (8 %) subpopulations was credited with
‘significant’ additional benefit, 2 (5%) with ‘marginal’, and 6 (16 %) with ‘additional
benefit not quantifiable’. The G-BA finally credited 18 out of 31 subpopulations
(58%) with ‘no proof of additional benefit’ or ‘less benefit’. A total of 2 (6%) subpopu-
lations were credited with ‘significant additional benefit’, 5 (16%) with ‘marginal
additional benefit’, and 6 (20%) with ‘additional benefit not quantifiable’.
CONCLUSIONS: The AMNOG evaluation of additional benefit differentiates a high
number of subpopulations. Obviously the number of subpopulations and the out-
comes varied between IQWiG assessment and final G-BA decision. So far, the ma-
jority of subpopulations were credited with ‘no proof of additional benefit’. First
results from reimbursement negotiations suggest that this may restrict price
agreement.
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OBJECTIVES: The Act on the Reform of the Market for Medicinal Products (AMNOG)
funds, effective since 01.01.2011, implemented an early benefit assessment of
drugs after launch in Germany. The Institute for Quality and Efficiency in Health
Care (IQWiG) assesses the benefit of a drug based on a dossier submitted by the
pharmaceutical manufacturer. Based on this assessment and the statements by
industry, scientific community and patient organizations the Federal Joint Com-
mittee (FJC) reviews and decides on the extent of the additional benefit being the
basis for price negotiations between the National Association of Statutory Health
Insurance Funds and the pharmaceutical manufacturer. The objective is to inves-
tigate possible differences between the scientific assessments by IQWiG and the
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subsequent decisions by FJC.METHODS:We examined all IQWiG assessments and
corresponding FJC decisions up to 01.06.2012 regarding possible disagreements.
Afterwards we categorized these findings and tried to identify schemes where FJC
regularly deviates from IQWiG’s recommendations. We excluded decisions on Or-
phan drugs because of the special regulations for these drugs. RESULTS: Totally 13
newly launched products were evaluated by IQWiG with subsequent decision on
additional benefit by the FJC. An additional benefit is not proven for more than 70%
of patient groups. The extent of the additional benefit doesn’t differ between as-
sessment and decision in 8 products. The FJC merges patient populations being
separately analyzed by IQWiG in 4 drugs. In case of Eribulin the result of IQWiG
assessment is no additional benefit in both subgroups whereas the FJC decides on
a slight and smaller benefit in the subgroups. Deviations in number of patients and
costs can’t be assessed, because IQWiG doesn’t always provide information on
these. CONCLUSIONS: Besides one case there are minor differences between as-
sessments and subsequent decisions. The impact of these differences on the price
negotiations is unknown until now.
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OBJECTIVES: The Act on the Reform of the Market for Medicinal Products (AMNOG)
funds, effective since 01.01.2011, implemented an early benefit assessment of
drugs after launch in Germany. This assessment is based on a dossier submitted by
the manufacturer for which the Federal Joint Committee (FJC) provides a detailed
template. The objective is to investigate the challenges within a pharmaceutical
company occurring during the preparation of a dossier. METHODS: First, the tem-
plate of FJC is analyzed to identify the data and skills needed to fulfill the require-
ments. These requirements are then linked to specialized departments within the
company. Finally, governance principles are developed. RESULTS: Data regarding
drug and disease, available treatments and guidelines, clinical study program as
well as German epidemiology and cost are needed for the dossier. Consequently,
profound skills in medicine, evidence-based medicine and biometrics are neces-
sary to support medical writing of the dossier. The departments Medical, Health
Economics & Outcomes Research (HEOR), Market Access, Regulatory, Commercial
and Legal are crucial for the development of a successful dossier. To finalize the
dossier in time, two teams are defined: One operational team with delegates from
Medical, HEOR and Regulatory prepares the dossier according to the FJC-require-
ments with or without support by an external vendor. Strategic decisions including
aspects not confined to the individual product are taken by the cross-functional
governance board. Beyond this a close alignment with global and regional Access
policies is essential. CONCLUSIONS: The preparation of a benefit dossier requires a
new area of cooperation at the local level within pharmaceutical companies involv-
ing a cross-functional team. Of particular importance are the HEOR and Regulatory
departments where essential information and expertise reside, putting these team
in the spotlight.
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OBJECTIVES: To assess the effort it takes for manufacturers to develop HTA sub-
missions in Germany and the UK and to compare it to the estimates proposed by
the legislator. METHODS: A review on available sources was conducted to assess
the proposed as well as the actual effort it takes to develop and submit a dossier to
the HTA agencies in Germany (G-BA/ IQWiG) and UK (NICE). Evidence from the
review was supplemented by interviews with experts from pharmaceutical and
consulting industry. RESULTS: The time proposed for HTA submission was partic-
ular low in Germany were the legislator estimated that a submission to the G-BA/
IQWiG could be done within 2.5 days. However, according to the review and expert
judgment actual effort of HTA submission in Germany required a minimum of one
year for multidisciplinary teams collaborating on generation of evidence following
the exact guidance that details the methods, contents, and format of submissions
to the German HTA body. Effort in UK is seen as lower due to the more collaborative
and interactive nature of the process avoiding unnecessary effort and allowing for
a clear focus on the critical questions. However, since the process in Germany is
still fairly new, it could be assumed that due to learning curve effort will be lower in
subsequent submission as the process gets more rationalized. CONCLUSIONS: The
actual burden exceeds the burden that was estimated particularly in Germany by
magnitudes. This study shows that the burden also depends on the organization of
the consulting process during dossier development. Whereas the early and struc-
tured interaction in UK was seen as favorable to avoid spending time on aspects
that are not relevant for the decision of the HTA body the highly formalized Ger-
man process where such an action is much less intense requires a more mecha-
nistic approach.
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OBJECTIVES: Since 2004 the National Institute of Health and Clinical Excellence
requires manufacturers to conduct a probabilistic sensitivity analysis for their
technology appraisals. The objective of this review is to assess the outcomes of
different probabilities of being cost effective and compare this with the actual
decision making done by NICE.METHODS: The search term “probabilistic sensitiv-
ity analysis” was used on NICE homepage (2012-01-25). The chapters included in
the search was assessed and included for further review if a probability of being
cost effective was provided regardless of what threshold was mentioned. If several
probabilities were provided the number provided by the evidence review group
were used rather than those provided by the manufacturer since these numbers
are more likely to be used in the decision making. If several scenarios were pre-
sented the base case scenario was chosen. Finally the probabilities of being cost
effective versus was compared with the actual decision making which could result
in 2 outcomes either it was recommended or not recommended. The results were
plotted into a graph to illustrate the relationship between PSA outcomes versus
final recommendation. The assessments were ranked according to their probabil-
ity of being cost effective. RESULTS: Thirty-one assessments were included for
final review. A higher probability of a technology being cost effective correlated to
more positive decision making and there even is observed a clear threshold where
technologies with a 40% certainty of being cost effective tend to be recommended
(3 out of 20) whereas those below are not recommended (2 out of 11) irrespective of
ICER. CONCLUSIONS: Reports suggested that ICER estimate was not a robust driver
of decision making. NICE applicant should provide an increase attention to PSA on
the top of ICER estimate.
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In Ireland, the National Centre for Pharmacoeconomics (NCPE) appraises the cost
effectiveness of technologies in response to requests from the Health Service Ex-
ecutive (HSE). A large number of reimbursement decisions are based upon the
appraisal of company Health Technology Assessments (HTAs). HTAs are con-
ducted in accordance with existing agreed Irish HTA Guidelines. These guidelines
do not specify the requirement of Expected Value of Perfect Information (EVPI)
analysis. OBJECTIVES: To examine the application of EVPI analysis as part of the
formal HTA process. METHODS: There is no set cost-effectiveness threshold in
Ireland; however, technologies with ICERs  €20,000/QALY are less likely to be
reimbursed. This threshold was considered here. EVPI estimates (at €20,000/QALY)
were determined directly from the PSA results of company economic models. Es-
timates were scaled up to 10 year population EVPI (PEVPI) levels. NCPE recommen-
dations on reimbursement were recorded. RESULTS: The NCPE have estimated
PEVPI values on nine company economic evaluations to date. All evaluations were
for newly licensed technologies; eight were pharmaceuticals and one was a diag-
nostic. Two technologies had ICERs €120,000 with PEVPI estimates €20 million;
reimbursement was not recommended. Two technologies dominated the relevant
comparators and one had an ICER €10,000/QALY. All PEVPI values were below €1
million. Reimbursement of all three technologies was recommended. The four
remaining technologies had ICERs in the range of €21,000/QALY -€30,000/QALY;
their PEVPI values ranged from about €1.5 million - €35 million. Reimbursement
was not recommended. In two cases (original PEVPI values of €2.4 million and €35
million respectively) the manufacturer subsequently revised the price. Reimburse-
ment was then recommended. There was no formal reanalysis of PEVPI.
CONCLUSIONS: To date, the formal analysis of PEVPI has not affected the decision
to accept or reject technologies with ICERs lower and higher than €20,000/QALY
respectively.
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OBJECTIVES: To illustrate how decision-making in England and Wales is influ-
enced by cost effectiveness and other factors, with particular emphasis on deci-
sions for end-of-life treatments. METHODS: An analysis of all technology apprais-
als published by the National Institute for Health and Clinical Excellence (NICE)
from 1st March 2000 to 31st May 2012 was conducted, with recommendations
categorised as ‘recommended’, ‘optimised, ‘not recommended’, ‘only in research’
and ‘non-submission’, by therapeutic area and by technology process (multiple
technology appraisal or single technology appraisal). These categories were then
mapped against the most plausible cost per QALY estimate and the recommenda-
tions were contextualised with the factors used in decision-making. RESULTS:
Since March 2000, NICE has published 256 appraisals containing 482 individual
recommendations on the use of technologies in England and Wales. The majority
(78%) of these decisions recommended the use of a technology either in line with its
licensed indication (‘recommended’) or under specific conditions (‘optimised’).
‘Only in research’ and ‘not recommended’ decisions represented 5% and 14% of all
recommendations respectively. Of the 135 recommendations in technology ap-
praisals which considered the use of oncology treatments, 61% were ‘recom-
mended’ or ‘optimised’. Since January 2009, 15 end-of-life technologies have been
considered of which 9 were recommended because the additional weight that
needed to be assigned to the QALY benefits was acceptable to justify these as an
appropriate use of NHS resources. Examples from other therapeutic areas show
how factors other than cost effectiveness have affected the recommendations,
such as equality considerations, or the impact of health-related benefits not cap-
tured in the QALY. CONCLUSIONS: NICE has provided guidance on a wide range of
new and established technologies, with the majority recommended for use. The
starting point for the decisions is the ICER in line with NICE’s commitment to
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